FINNENCE ▪ THE WIRE FILE
THE WIRE · № 60914
Company▲ Bullish
Phase 3 results posted: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor — Eli Lilly and Company
KINDCompany
DIRECTION▲ Bullish
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-10-01 12:00 UTC
LAST UPDATE2026-10-01 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Completed Phase 3 for Lilly's oral GLP-1 in diabetes advances a key obesity/diabetes franchise.
Oral GLP-1 advances Lilly's metabolic pipeline
CATALYST TO WATCH
Data disclosure and regulatory filing
MAIN RISK
Efficacy or safety may disappoint
FULL DISPATCH
Sponsor: Eli Lilly and Company; Status: Completed; Conditions: Type 2 Diabetes; Interventions: Orforglipron, Placebo; Enrollment: 546 (actual); First posted: 2023-10-31; Results posted: 2026-10-01; NCT: NCT06109311
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTEli Lilly · LLY
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Phase 3 results posted: Atacicept in Subjects With IgA Nephropathy — Vera Therapeutics, Inc.2026-10-01 12:00 UTC
Phase 3 results posted: Atacicept in Subjects With IgA Nephropathy — Vera Therapeutics, Inc.2026-10-01 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia — Biosplice Therapeutics, Inc.2026-10-01 12:00 UTC
Phase 3 results posted: A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia — Biosplice Therapeutics, Inc.2026-10-01 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III) — BioXcel Therapeutics Inc2026-10-01 12:00 UTC
Phase 3 results posted: Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III) — BioXcel Therapeutics Inc2026-10-01 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis — Abcuro, Inc.2026-10-01 12:00 UTC
Phase 3 results posted: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis — Abcuro, Inc.2026-10-01 12:00 UTC
→CORRELATIONshares Healthcare
Quadria-backed Maxivision confidentially files for India IPO2026-10-01 23:00 UTC
Quadria-backed Maxivision confidentially files for India IPO2026-10-01 23:00 UTC
→CORRELATIONshares Healthcare
Supreme Court denies Arizona’s bid to delay start of takeover of healthcare in state prisons2026-10-01 17:58 UTC
Supreme Court denies Arizona’s bid to delay start of takeover of healthcare in state prisons2026-10-01 17:58 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.